SCHEMBL4242228

SCHEMBL4242228

CCCCN1CCC(Oc2cc(F)c(C(=O)O)cc2C)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
HTR4 Q13639 5/20 0.41
ADRA2B P18089 2/20 0.41
ADRA1A P35348 2/20 0.41
ADRA1B P35368 2/20 0.41
ADRA2C P18825 1/20 0.41
HTR1D P28221 1/20 0.41
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41
CHRM3 P20309 2/20 0.40
HRH2 P25021 1/20 0.40
HRH1 P35367 6/20 0.39
CCR3 P51677 2/20 0.39
ACHE P22303 2/20 0.39
HRH3 Q9Y5N1 1/20 0.39
KDM4E B2RXH2 1/20 0.39
KCNH2 Q12809 3/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4238943 0.91 HTR4 (0.45) MAOAMAOBHTR4ADRA2BADRA1A
SCHEMBL4238793 0.81 MAOA (0.43) MAOAMAOBHTR4HTR2CHTR2B
SCHEMBL4231828 0.81 MAOA (0.53) MAOAMAOBHTR4HTR2CHTR2B
SCHEMBL4226863 0.80 HRH3 (0.47) MAOAMAOBHTR4ADRA1BADRA2C
SCHEMBL4237668 0.79 HRH3 (0.44) MAOAMAOBHTR4ADRA2BADRA1A
SCHEMBL4232317 0.79 SSTR5 (0.46) MAOAMAOBHTR4ADRA1BADRA2C
SCHEMBL4227908 0.77 MAOA (0.56) MAOAMAOBHTR4HTR2CHTR2B
SCHEMBL4238046 0.76 MAOA (0.47) MAOAMAOBHTR4ADRA1BADRA2C
SCHEMBL4233901 0.75 ALDH1A1 (0.45) HTR2CKDM4EHTR1ADRD2DRD4
SCHEMBL19460667 0.74 KCNH2 (0.56) CHRM3HRH2KDM4EKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R MAOA 219/4885MAOB 169/4885HTR4 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.